FDA Eliminates Two-Trial Requirement for Drug Approvals, Shifting to Single-Trial Default

The FDA has implemented a significant policy shift by removing the requirement for two clinical trials for drug approvals, transitioning to a single trial default approach designed to expedite drug approval processes and enhance patient access to new therapies.

Enhanced Post-Market Surveillance Strategy

According to Ron Lanton, Senior Partner & Global Strategist at Lanton, Lanton & Sosa Law PLLC (搜索)搜索该词条, this represents "a really major policy shift" with a key differentiating factor from previous FDA policies. "The one interesting thing that's a little bit different than in previous FDA policies is that they want to do a more robust post market surveillance to make sure that if they do approve something, that they are watching this, to make sure that there are no adverse effects," Lanton explained.

Manufacturer Response and Resource Allocation

The policy change is prompting pharmaceutical companies to restructure their development strategies. Manufacturers will need to consolidate their efforts into what Lanton describes as "one super trial." He notes that "every effort that they had before is just going to be shrunk into the one super trial. So they're going to want to make sure that they combine enough resources in here to make it so that, yes, you know this is going to be producing the same result and so forth."

Pricing and Risk Management Implications

Despite the potential for reduced development costs, drug pricing may not decrease proportionally. Lanton suggests that companies may maintain elevated pricing as a risk mitigation strategy: "I do think, though, that there is the risk that drugs will not be priced any lower, simply because it's kind of like a savings bank or something like that, where, what if this doesn't work? Or what if post market surveillance notices something else and the drug has to be pulled."

The concern centers on R&D cost recovery in an uncertain regulatory environment. "So do we recoup our R&D cost faster? Or how can we do that? Maybe one way is just to keep the drug cost elevated, just until we make sure the coast is clear," Lanton explained.

Litigation Risks and Internal Protocols

The single-trial pathway introduces new liability considerations for manufacturers. "If I'm a manufacturer and I have less trials, there's always that risk management of, is it going to be okay? Is everything going to work, and if it doesn't, are we going to be sued? That is very real," Lanton noted.

Companies are expected to implement additional internal risk management protocols as standard operating procedures. While manufacturers may conduct additional internal trials before seeking approval, these are likely to be less robust than traditional approaches.

Priority Review Voucher Program

Manufacturers may increasingly utilize the FDA's Commissioner's National Priority Voucher program, which can reduce review times from the standard six months to one to two months. However, participation requires alignment with specific administration goals, including increasing affordability, meeting unmet medical needs, addressing public health crises, and onshoring manufacturing operations to the United States.

The policy shift represents uncharted territory for the pharmaceutical industry, with Lanton emphasizing that "this is something that's brand new for everybody." The long-term implications for drug development, safety monitoring, and market access will likely become clearer as companies adapt to this new regulatory framework.